Oxidized lipids as molecular biomarkers in carotid in-stent restenosis: mechanisms and clinical implications
-
By
-
Qiao Chen
-
Haifeng Shao
-
Zhaohui He
-
Ping Ni
-
Nengwei Yu
-
Binghu Li
-
Suping Li
-
May 4, 2026
-
Clinical Scorecard: Molecular Biomarkers of Oxidized Lipids in Carotid In-Stent Restenosis: Mechanistic Insights and Clinical Significance
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients undergoing carotid artery stenting (CAS), particularly high-risk surgical patients. |
| Care Setting | |
Key Highlights
- ISR occurs in 10–30% of patients within the first year after CAS.
- Oxidized lipids serve as bioactive molecules promoting vascular inflammation and smooth muscle cell proliferation.
- Distinct oxidized lipid species, such as oxidized phospholipids and ox-LDL, are associated with ISR risk and severity.
- Emerging therapeutic strategies target oxidized lipid pathways to prevent ISR.
- Advances in lipidomics enable precise identification of oxidized lipid biomarkers.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regular assessment of specific oxidized lipid levels in patients post-CAS.
Risks
Patient & Prescribing Data
Patients with carotid artery stenosis undergoing stenting.
Targeting oxidized lipid pathways may improve outcomes and reduce ISR incidence.
Clinical Best Practices
- Integrate mechanistic insights of oxidized lipids into clinical practice for ISR management, including specific assessment protocols.
- Monitor oxidative stress markers in patients post-stenting.
References
